Bio News

Lifemine Therapeutics has secured a $188 million Series E investment from Bill Gates and Jeff Bezos. The investment gives Lifemine four times its original fundraising target. The company plans to begin a phase 2 trial of the immunosuppressant “LIFE-001” in 150 kidney transplant recipients early next year.

Biobook Team
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882